Corinne Faivre-Finn, FRCR, MD, PhD

Search results

• 2022

  Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation, and region in England and Wales during 2020: A registry-based study

  Kontopantelis, E., Mamas, M. A., Webb, R. T., Castro, A., Rutter, M. K., Gale, C. P., Ashcroft, D. M., Pierce, M., Abel, K. M., Price, G., Faivre-Finn, C., Van Spall, H. G. C., Graham, M. M., Morciano, M., Martin, G. P., Sutton, M. & Doran, T., 15 Feb 2022, In: PLOS Medicine. 19, 2, e1003904.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Disease 100%
  • Coronavirinae 100%
  • COVID-19 100%
  • Cardiovascular Disease 20%
  • Malignant Neoplasm 20%

• Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey

  Pilotto, S., Avancini, A., Menis, J., Sperduti, I., Giaj Levra, M., Berghmans, T., Bironzo, P., Brandão, M., De Ruysscher, D., Edwards, J., Faivre-Finn, C., Girard, N., Greillier, L., Hendriks, L., Lantuejoul, S., Mauer, M., Novello, S., O'Brien, M., Reck, M. & Reguart, N. & 5 others, Remon, J., von der Thüsen, J., Dingemans, A.-M. C., Besse, B. & Milella, M., 1 Jul 2022, In: Lung cancer (Amsterdam, Netherlands). 169, p. 94-101 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Health Care Personnel 100%
  • Lung Cancer 100%
  • Disease 28%
  • Patient Referral 28%
  • Diseases 28%

• Experience with the first three lung cancer patients to receive magnetic resonance (MR)-guided radiotherapy on the Elekta Unity MR-Linac in the United Kingdom (UK)

  Crockett, C., Benson, R., Berresford, J., Chuter, R., Clough, A., Faivre-Finn, C., Freear, L., Marchant, T., Nelder, C., Pitt, E. & Salem, A., Mar 2022, In: Lung Cancer. 165, p. S50-S51

  Research output: Contribution to journal › Article › peer-review

• Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020

  Kearney, M., Keys, M., Faivre-Finn, C., Wang, Z., Aznar, M. C. & Duane, F., 1 Jul 2022, In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 172, p. 118-125 8 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Lung Cancer 100%
  • Cancer Radiotherapy 100%
  • Radiation Therapy 75%
  • Intensity Modulated Radiation Therapy 50%
  • Neoplasm 25%

• Feasibility of low-dose 4DCBCT for patient setup and motion measurement

  Lindsay, J., Bryce-Atkinson, A., Meara, S., Faivre-Finn, C., Eccles, C., Aznar, M. & van Herk, M., May 2022, In: Radiotherapy and Oncology. 170, p. S1422-S1425 5 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

  Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., Rimner, A., Wu, Y.-L., Özgüroğlu, M., Lee, K. H., Kato, T., Wit, M. D., Kurata, T., Reck, M., Cho, B. C. & Senan, S. & 5 others, Naidoo, J., Mann, H., Newton, M., Thiyagarajah, P. & Antonia, S. J., 2 Feb 2022, In: Journal of Clinical Oncology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer

  Banfill, K., Abravan, A., van Herk, M., Sun, F., Franks, K., McWilliam, A. & Faivre-Finn, C., 11 Oct 2022, In: Frontiers in Oncology. 12, 1007577.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lung Cancer 100%
  • Radiation Therapy 100%
  • Hypofractionated Radiotherapy 100%
  • Cumulative Incidence 75%
  • Heart Death 75%

• Impact of introducing intensity modulated radiotherapy (IMRT) on curative intent radiotherapy and survival for lung cancer

  Chan, C., Fornacon-Wood, I., Bayman, N., Banfil, K., Coote, J., Garbett, A., Harris, M., Hudson, A., Kennedy, J., Pemberton, L., Price, G., Salem, A., Sheikh, H., Whitehurst, P., Woolf, D. & Faivre-Finn, C., Mar 2022, In: Lung Cancer. 165, p. S49

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Impact of Introducing Intensity Modulated Radiotherapy on Curative Intent Radiotherapy and Survival for Lung Cancer

  Fornacon-Wood, I., Chan, C., Bayman, N., Banfill, K., Coote, J., Garbett, A., Harris, M., Hudson, A., Kennedy, J., Pemberton, L., Salem, A., Sheikh, H., Whitehurst, P., Woolf, D., Price, G. & Faivre-Finn, C., 31 May 2022, In: Frontiers in Oncology. 12, 835844.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lung Cancer 100%
  • Radiation Therapy 100%
  • Intensity Modulated Radiation Therapy 100%
  • Neoplasm 100%
  • Curative Dose 50%

• Impact on quality of life from multi-modality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multi-modality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)

  Taylor, S., Tsim, S., Navani, N., Baldwin, D., Woolhouse, I., Edwards, J., Grundy, S., Robson, J., Rhodes, S., Burnside, N., Blackhall, F., Faivre-Finn, C., Yorke, J. & Evison, M., Mar 2022, In: Lung Cancer. 165, p. S69

  Research output: Contribution to journal › Article › peer-review

• Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE

  Walker, K., Hinsley, S., Phillip, R., Oughton, J. B., Murden, G., Chalmers, A. J., Faivre-Finn, C., Greystoke, A. & Brown, S. R., Nov 2022, In: JCO Precision Oncology.

  Research output: Contribution to journal › Article › peer-review

• Initial Clinical Experience of Routine Electronic Patient-Reported Outcome Measures at the Christie NHS Foundation Trust

  Crockett, C., Faivre-Finn, C., Yorke, J. & Price, J., Apr 2022, In: Clinical Oncology. 34, 4, p. e168

  Research output: Contribution to journal › Letter › peer-review

• Initial experience delivering stereotactic radiotherapy to a gluteal metastasis on a 1.5T MR Linac

  Amaro, P., McDaid, L., Davies, L., Whiteside, L., Clough, A., Faivre-Finn, C., Parker, J., Bailey, R., Benson, R., Nelder, C., Pitt, E., Eccles, C., Crockett, C., Salem, A. & Choudhury, A., May 2022, In: Radiotherapy and Oncology. 170, p. S1662-S1663 2 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Initial findings following the routine implementation of electronic patient reported outcome measures (ePROMs) for patients with lung cancer at the Christie NHS Foundation Trust

  Crockett, C., Bayman, N., Chan, C., Coote, J., Harris, M., Pemberton, L., Salem, A., Sheikh, H., Woolf, D., Yorke, J. & Faivre-Finn, C., Mar 2022, In: Lung Cancer. 165, p. S8

  Research output: Contribution to journal › Article › peer-review

• OC-0437 Impact of introducing IMRT on curative intent radiotherapy and survival for lung cancer

  Chan, C., Fornacon-Wood, I., Bayman, N., Banfil, K., Coote, J., Garbett, A., Harris, M., Hudson, A., Kennedy, J., Pemberton, L., Price, G., Salem, A., Sheikh, H., Whitehurst, P., Woolf, D. & Faivre-Finn, C., May 2022, In: Radiotherapy and Oncology. 170, p. S380-S381

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Outcomes With Durvalumab after Chemoradiotherapy in Stage IIIA-N2 Non-small-cell Lung Cancer: an Exploratory Analysis from the PACIFIC Trial

  Senan, S., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Murakami, S., Hui, R., Faivre-Finn, C., Paz-Ares, L., Wu, Y., Mann, H., Dennis, P. A. & Antonia, S. J., 1 Feb 2022, (Accepted/In press) In: ESMO Open.

  Research output: Contribution to journal › Article › peer-review

  • Non Small Cell Lung Cancer 100%
  • Durvalumab 100%
  • Disease 42%
  • Placebo 42%
  • Disease Exacerbation 28%

• Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)

  REQUITE consortium, 1 Apr 2022, In: Lung cancer (Amsterdam, Netherlands). 166, p. 228-241 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Symptom 100%
  • Deterioration 100%
  • Non Small Cell Lung Cancer 100%
  • Pneumonitis 100%
  • Dermatitis 100%

• Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC

  Faivre-Finn, C., Edwards, J. G. & Hatton, M., 1 Feb 2022, In: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17, 2, p. 197-199 3 p.

  Research output: Contribution to journal › Editorial › peer-review

• Prise en charge des formes oligométastatiques: l'avis de l'oncologue thoracique

  Molinier, O., Guguen, C., Moro-Sibilot, D., Besse, B. & Faivre-Finn, C., Oct 2022, In: Revue des Maladies Respiratoires Actualites. 14, 2, p. 2S151-2S161

  Research output: Contribution to journal › Article › peer-review

• Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell Lung Cancer: a scoping review

  Liao, K., Wang, T., Coomber-Moore, J., Wong, D. C., Gomes, F., Faivre-Finn, C., Sperrin, M., Yorke, J. & van der Veer, S. N., 1 Dec 2022, In: BMC Cancer. 22, 1, p. 1076 1076.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Scoping Review 100%
  • Prognostic Model 100%
  • Non Small Cell Lung Cancer 100%
  • Patient-Reported Outcome 100%
  • Prognostic Factor 36%

• Publisher Correction: Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI (Nature Medicine, (2022), 28, 5, (924-933), 10.1038/s41591-022-01772-9)

  DECIDE-AI expert group, Oct 2022, In: Nature Medicine. 28, 10, p. 2218 1 p.

  Research output: Contribution to journal › Commentary/debate › peer-review

  Open Access

  • Artificial Intelligence 100%

• Radial Data Mining to Identify Density-Dose Interactions That Predict Distant Failure Following SABR

  Davey, A., van Herk, M., Faivre-Finn, C. & McWilliam, A., 9 Mar 2022, In: Frontiers in Oncology. 12, p. 838155

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Data Mining 100%
  • Neoplasm 100%
  • Gross Tumor Volume 100%
  • Tomography 50%
  • Pretreatment 50%

• Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer

  Rimner, A., Lai, W.-C. V., Califano, R., Jabbour, S. K., Rudin, C. M., Faivre-Finn, C., Cho, B. C., Kato, T., Yu, J., Chafin, W., Yu, L., Zhao, B. & Byers, L., 1 Jul 2022, In: Clinical Lung Cancer. 23, 5, p. e325-e329 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Small Cell Lung Cancer 100%
  • Chemoradiotherapy 100%
  • Olaparib 100%
  • Pembrolizumab 100%
  • Placebo 44%

• Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI

  DECIDE-AI expert group, May 2022, In: Nature Medicine. 28, 5, p. 924-933 10 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Checklist 100%
  • Artificial Intelligence 100%
  • Clinical Study 100%
  • Patient Care 50%
  • In Silico 50%

• Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy

  Abravan, A., Price, G., Banfill, K., Merchant, T., Craddock, M., Wood, J., Aznar, M. C., Mcwilliam, A., Van Herk, M. & Faivre-Finn, C., 13 Jun 2022, (Accepted/In press) In: Frontiers in Oncology.

  Research output: Contribution to journal › Article › peer-review

  • Cardiotoxicity 100%
  • Lung Cancer 100%
  • Heart Disease 66%

• Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

  Bischoff, H., Garassino, M., Mazieres, J., Reck, M., Chouaid, C., Cove-Smith, L., Mansy, T., Migliorino, M., Delmonte, A., Sanchez, J., Velarde, L., Bernabe, R., Paz-Ares, L., Perez, I., Trunova, N., Foroutanpour, K., Faivre-Finn, C. & Reinmuth, N., Nov 2022, In: Oncology Research and Treatment. 45, SUPPL 3, p. 160-161 2 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• SARON: stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer (NSCLC)

  Mak, K.-M., McDonald, F., Teague, J., Faivre-Finn, C., Forster, M., Hanna, G., Moinuddin, S., Conibear, J., Harden, S., Popat, S., Califano, R., Farrelly, L., Counsell, N. & TMG, S., Mar 2022, In: Lung Cancer. 165, p. S71

  Research output: Contribution to journal › Article › peer-review

• Service evaluation of MyChristie-MyHealth, an electronic patient reported outcome measure integrated into clinical cancer care

  Shipman, L., Chan, C., Faivre-Finn, C., Fenemore, J., Harris, M., Salem, A., Sheikh, H. & Woolf, D., Mar 2022, In: Lung Cancer. 165, p. S66

  Research output: Contribution to journal › Article › peer-review

• Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead

  Willers, H., Krause, M., Faivre-Finn, C. & Chalmers, A. J., 1 Feb 2022, In: International journal of radiation oncology, biology, physics. 112, 2, p. 265-270 6 p.

  Research output: Contribution to journal › Editorial › peer-review

• The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study: Symptoms, toxicity and quality of life of lung cancer patients

  REQUITE consortium, Nov 2022, In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 176, p. 127-137 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lung Cancer 100%
  • Radiation Therapy 100%
  • Non Small Cell Lung Cancer 100%
  • Symptom 100%
  • Disease 40%

• The Role of Electronic Patient-Reported Outcome Measures in Assessing Smoking Status and Cessation for Patients with Lung Cancer

  Convill, J., Blackhall, F., Yorke, J., Faivre-Finn, C. & Gomes, F., Dec 2022, In: Oncology and Therapy. 10, 2, p. 481-491 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Patient-Reported Outcome 100%
  • Clinician 100%
  • Lung Cancer 100%
  • Nicotine Withdrawal 44%
  • Cancer Center 33%

• To what extent, how and how robustly have patientreported outcome measures (PROMs) been investigated as prognostic factors in non-small cell lung cancer: a scoping review

  Liao, K., Wang, T., Coomber-Moore, J., Wong, D., Gomes, F., Faivre-Finn, C., Sperrin, M., Yorke, J. & Van der Veer, S., Nov 2022, In: Quality of Life Research . 31, p. S93-S94 2 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Unaccounted Confounders Limit the Ability to Draw Conclusions From Big Data Analysis Comparing Radiotherapy Fractionation Regimens in NSCLC

  Salem, A., Franks, K., Greystoke, A., Hanna, G. G., Harrow, S., Hatton, M., Hiley, C., McDonald, F. & Faivre-Finn, C., Jun 2022, In: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17, 6, p. e55-e56

  Research output: Contribution to journal › Letter › peer-review

• Understanding the Differences Between Bayesian and Frequentist Statistics

  Fornacon-Wood, I., Mistry, H., Johnson-Hart, C., Faivre-Finn, C., O'Connor, J. P. B. & Price, G. J., 1 Apr 2022, In: International journal of radiation oncology, biology, physics. 112, 5, p. 1076-1082 7 p.

  Research output: Contribution to journal › Editorial › peer-review
• 2021

  1748 Electronic Patient Reported Outcome Measures: Next Generation Cancer Patient Monitoring?

  Shipman, L. A. & Faivre-Finn, C., Oct 2021.

  Research output: Contribution to conference › Paper › peer-review

• A novel use for routine CBCT imaging during radiotherapy to detect COVID-19

  Clough, A., Sanders, J., Banfill, K., Faivre-Finn, C., Price, G., Eccles, C. L., Aznar, M. C. & Van Herk, M., 22 Jun 2021, In: Radiography.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radiation Therapy 100%
  • Volume CT 100%
  • COVID-19 100%
  • Radiotherapy 100%
  • Cone Beam Computed Tomography 100%

• Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung)

  Banfill, K. B., Price, G., Wicks, K., Ahmad, S., Bainbridge, H., Bayne, M., Britten, A., Carson, C., Dorey, N., Goranov, B., Guglani, S., Harland, K., Hatton, M., Jayaprakash, T. K., Hiley, C., Jegannathen, A., Koh, P., Lord, H., Mokhtar, D. & Panakis, N. & 10 others, Peedell, C., Pope, T., Peters, A., Powell, C., Stilwell, C., Treece, S., Thomas, B., Toy, E., Zhou, S. & Faivre-Finn, C., Jun 2021, In: Lung Cancer. 156, p. S14-S14

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK

  Banfill, K., Croxford, W., Fornacon-wood, I., Wicks, K., Ahmad, S., Britten, A., Carson, C., Dorey, N., Hatton, M., Hiley, C., Thippu Jayaprakash, K., Jegannathen, A., Koh, P., Panakis, N., Peedell, C., Pope, A., Powell, C., Stilwell, C., Thomas, B. & Toy, E. & 5 others, Wood, V., Yahya, S., Zhou, S. Y., Price, G. & Faivre-finn, C., 27 Oct 2021, In: Clinical Oncology.

  Research output: Contribution to journal › Article › peer-review

  • Lung Cancer 100%
  • Radiation Therapy 100%
  • COVID-19 100%
  • Pandemic 100%
  • Disease 50%

• Efficient Visualisation of Changes in CBCT During Radiotherapy to Detect Lung Infections

  van Herk, M., Price, G., Clough, A., Sanders, J., Faivre-Finn, C., Eccles, C. & Aznar, M., Jun 2021, In: Medical Physics. 48, 6

  Research output: Contribution to journal › Meeting Abstract › peer-review

• EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer

  Foy, V., Lindsay, C. R., Carmel, A., Fernandez-Gutierrez, F., Krebs, M. G., Priest, L., Carter, M., Groen, H. J. M., Hiltermann, T. J. N., de Luca, A., Farace, F., Besse, B., Terstappen, L., Rossi, E., Morabito, A., Perrone, F., Renehan, A., Faivre-Finn, C., Normanno, N. & Dive, C. & 2 others, Blackhall, F. & Michiels, S., 1 Apr 2021, In: Translational Lung Cancer Research. 10, 4, p. 1653-1665 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Small Cell Lung Cancer 100%
  • Circulating Tumor Cell 100%
  • Pooled Analysis 100%
  • Cell Count 100%
  • Hazard Ratio 31%

• Evaluation of prognostic & predictive models in the oncology clinic

  Craddock, M., Crockett, C. B., Mcwilliam, A., Price, G., Sperrin, M., van der Veer, S. & Faivre-Finn, C., 25 Nov 2021, (Accepted/In press) In: Clinical Oncology.

  Research output: Contribution to journal › Article › peer-review

  • Life Cycle 100%
  • Clinical Decision Making 100%

• Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales

  Kontopantelis, E., Mamas, M., Webb, R., Castro, A. I., Rutter, M. K., Gale, C. P., Ashcroft, D., Pierce, M., Abel, K., Price, G., Faivre-Finn, C., Van Spall , H. G. C., Graham, M. M., Morciano, M., Martin, G. & Doran, T., 3 May 2021, (Accepted/In press) In: The Lancet Regional Health – Europe.

  Research output: Contribution to journal › Article › peer-review

  • Cardiovascular Disease 100%
  • COVID-19 100%
  • Malignant Neoplasm 66%
  • Diabetes 42%
  • Infection 33%

• Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales: A retrospective registry study

  Kontopantelis, E., Mamas, M. A., Webb, R. T., Castro, A., Rutter, M. K., Gale, C. P., Ashcroft, D. M., Pierce, M., Abel, K. M., Price, G., Faivre-Finn, C., Van Spall, H. G. C., Graham, M. M., Morciano, M., Martin, G. P. & Doran, T., 7 Jun 2021, In: The Lancet Regional Health – Europe. 7, p. 100144 100144.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Cardiovascular Disease 100%
  • COVID-19 100%
  • Malignant Neoplasm 66%
  • Diabetes 42%
  • Infection 33%
  167 Downloads (Pure)

• Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation and region in England & Wales during 2020

  Kontopantelis, E., Mamas, M. A., Webb, R. T., Castro-Avila, A., Rutter, M. K., Gale, C. P., Ashcroft, D. M., Pierce, M., Abel, K. M., Price, G., Faivre-Finn, C., Spall, H. G. C. V., Graham, M. M., Morciano, M., Martin, G. P., Sutton, M. & Doran, T., 7 Jul 2021, In: medRxiv.

  Research output: Contribution to journal › Article › peer-review

• Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

  Spigel, D., Faivre-Finn, C., Gray, J., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J., Garassino, M., Hui, R., Quantin, X., Rimner, A., Wu, Y., Ozguroglu, M., Lee, K., Kato, T., de Wit, M., Macpherson, E., Newton, M., Thiyagarajah, P. & Antonia, S., 20 May 2021, In: Journal of Clinical Oncology. 39, 15, 3 p.

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

  Faivre-Finn, C., Vicente, D., Kurata, T., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Spigel, D. R., Garassino, M. C., Reck, M., Senan, S., Naidoo, J., Rimner, A., Wu, Y. L., Gray, J. E., Özgüroğlu, M., Lee, K. H., Cho, B. C., Kato, T., de Wit, M. & Newton, M. & 3 others, Wang, L., Thiyagarajah, P. & Antonia, S. J., May 2021, In: Journal of Thoracic Oncology. 16, 5, p. 860-867 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Overall Survival 100%
  • Progression Free Survival 100%
  • Durvalumab 100%
  • Placebo 87%
  • Survival Rate 37%

• HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours

  McDonald, F., Guckenberger, M., Popat, S., Faivre-Finn, C., Andratschke, N., Riddell, A., Hanna, G., Prakash, V., Nair, A., Diez, P., Patel, P., Kilburn, L., Toms, C. & Bliss, J., Jun 2021, In: Lung Cancer. 156, p. S70-S71

  Research output: Contribution to journal › Meeting Abstract › peer-review

• Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)

  Taylor, S., Yorke, J., Tsim, S., Navani, N., Baldwin, D., Woolhouse, I., Edwards, J., Grundy, S., Robson, J., Rhodes, S., Gomes, F., Blackhall, F., Faivre-Finn, C. & Evison, M., 15 Jul 2021, In: BMJ Open Respiratory Research. 8, 1

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lung Cancer 100%
  • Non Small Cell Lung Cancer 100%
  • Radiation Therapy 25%
  • Local Therapy 25%

• Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer

  Crockett, C. B., Samson, P., Chuter, R., Dubec, M., Faivre-Finn, C., Green, O. L., Hackett, S. L., McDonald, F., Robinson, C., Shiarli, A. M., Straza, M. W., Verhoeff, J. J. C., Werner-Wasik, M., Vlacich, G. & Cobben, D., 10 Mar 2021, In: Frontiers in Oncology. 11, 617681.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radiation Therapy 100%
  • Non Small Cell Lung Cancer 100%
  • Neoplasm 16%
  • Lung Cancer 16%
  • Non-Small Cell Lung Cancer 16%

• Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study

  Haslett, K., Bayman, N., Franks, K., Groom, N., Harden, S. V., Harris, C., Hanna, G., Harrow, S., Hatton, M., McCloskey, P., McDonald, F., Ryder, W. D. & Faivre-Finn, C., 1 Apr 2021, In: International Journal of Radiation Oncology Biology Physics. 109, 5, p. 1341-1348 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Non Small Cell Lung Cancer 100%
  • Intensity Modulated Radiation Therapy 100%
  • Radiation Therapy 60%
  • Chemotherapy 33%
  • Neoplasm 33%